高磊,陈韵岱

• 1:中国人民解放军总医院第六医学中心心血管病医学部

摘要(Abstract)：

《中国介入心脏病学杂志》2023年6月发表了《药物涂层球囊临床应用中国专家共识（第二版）》，共识结合近年来药物涂层球囊在冠心病介入治疗领域的循证医学证据，对药物涂层球囊的适应证、规范操作、腔内影像和冠状动脉功能学在药物涂层球囊治疗中的应用等进行了更新。本文结合临床诊疗实践和循证医学证据，就该共识亮点进行解读，以期为临床实践提供参考。

关键词(KeyWords)： 药物涂层球囊;支架内再狭窄;冠状动脉原发病变;专家共识

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 高磊,陈韵岱

参考文献(References)：

• [1]《药物涂层球囊临床应用中国专家共识（第二版）》专家组.药物涂层球囊临床应用中国专家共识（第二版）[J].中国介入心脏病学杂志，2023, 31(6):413-426. DOI:10.3969/j.issn.1004-8812.2023.06.003.
• [2]《药物涂层球囊临床应用中国专家共识》专家组.药物涂层球囊临床应用中国专家共识[J].中国介入心脏病学杂志，2016,24(2):61-67.DOI:10.3969/j. issn.1004-8812.2016.02.001.
• [3]李占鲁，黄翯.紫杉醇涂层球囊的应用现状和不足以及新一代药物涂层球囊的研究进展[J].中国介入心脏病学杂志，2022,30(4):299-302. DOI:10.3969/j.issn.1004-8812.2022.04.009.
• [4] Yerasi C, Case BC, Forrestal BJ, et al. Drug-coated balloon for de novo coronary artery disease:JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 75(9):1061-1073.DOI:10.1016/j.jacc.2019.12.046.
• [5] Chen Y, Gao L, Qin Q, et al. Comparison of 2 dif ferent drug-coated balloons in in-stent restenosis:the RESTORE ISR China randomized trial[J]. JACC Cardiovasc Interv, 2018,11(23):2368-2377. DOI:10.1016/j.jcin.2018.09.010.
• [6] Liu S, Zhou Y, Shen Z, et al. A randomized comparison of 2dif ferent drug-coated balloons for in-stent restenosis[J]. JACC Cardiovasc Interv,2023,16(7):759-767. DOI:10.1016/j.jcin.2022.12.018.
• [7] Byrne RA, Durand R. Sirolimus-coated balloon angioplasty for coronary artery disease:one step forward, two steps back[J].JACC Cardiovasc Interv,2023,16(23):2897-2899. DOI:10.1016/j.jcin.2023.11.010.
• [8] Vos NS, Fagel ND, Amoroso G, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction:the REVELATION randomized trial[J]. JACC Cardiovasc Interv, 2019, 12(17):1691-1699. DOI:10.1016/j.jcin.2019.04.016.
• [9] W?hrle J, Scheller B, Seeger J, et al. Impact of diabetes on outcome with drug-coated balloons versus drug-eluting stents:the BASKET-SMALL 2 trial[J]. JACC Cardiovasc Interv, 2021, 14(16):1789-1798. DOI:10.1016/j.jcin.2021.06.025.
• [10] Rissanen TT, Uskela S, Er?nen J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk(DEBUT):a single-blind, randomised,non-inferiority trial[J]. Lancet, 2019, 394(10194):230-239. DOI:10.1016/S0140-6736(19)31126-2.
• [11]王宁远，冯欢欢，王威，等.光学相干断层成像指导准分子激光联合药物涂层球囊治疗复发性支架内再狭窄的初步研究[J].中国介入心脏病学杂志，2023,31(8):579-584.DOI:10.3969/j.issn.1004-8812.2023.08.003.
• [12] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J, 2019, 40(2):87-165. DOI:10.1093/eurheartj/ehy394.
• [13] Klein LW, Nathan S, Maehara A, et al. SCAI Expert Consensus Statement on Management of In-Stent Restenosis and Stent Thrombosis[J]. JSCAI, 2023. DOI:10.1016/j.jscai.2023.100971.
• [14]王泉，黄河，吉港，等，宋婧.紫杉醇药物涂层球囊治疗冠状动脉原位病变出现晚期管腔扩大的血管内超声观察[J].中国介入心脏病学杂志，2022,30(7):522-529. DOI:10.3969/j.issn.1004-8812.2022.07.008.
• [15] Fanggiday JC,Stella PR,Guyomi SH,et al. Safety and e ffi cacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions:the DEBIUT(drug-eluting balloon in bifurcation Utrecht)registry[J]. Catheter Cardiovasc Interv. 2008,71(5):629-635. DOI:10.1002/ccd.21452.
• [16] Jing QM,Zhao X,Han YL,et al. A drug-eluting balloon for the treatment of coronary bifurcation lesions in the side branch:a prospective multicenter randomized(BEYOND)clinical trial in China[J]. Chin Med J(Engl),2020,133(8):899-908.DOI:10.1097/CM9.0000000000000743.
• [17] Pan L, Lu W, Han Z, et al. Drug-coated balloon in the treatment of coronary left main true bifurcation lesion:a patient-level propensity-matched analysis[J]. Front Cardiovasc Med, 2022,9:1028007. DOI:10.3389/fcvm.2022.1028007.
• [18] Chung JH, Lee KE, Her AY, et al. Comparison of fractional flow reserve and angiographic characteristics after balloon angioplasty in de novo coronary lesions[J]. Int J Cardiovasc Imaging, 2019, 35(11):1945-1954. DOI:10.1007/s10554-019-01649-y.
• [19] Her AY, Shin ES, Bang LH, et al. Drug-coated balloon treatment in coronary artery disease:recommendations from an Asia-Pacific Consensus Group[J]. Cardiol J, 2021, 28(1):136-149. DOI:10.5603/CJ.a2019.0093.
• [20] Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drugcoated balloons for coronary artery disease:third report of the International DCB Consensus Group[J]. JACC Cardiovasc Interv, 2020, 13(12):1391-1402. DOI:10.1016/j.jcin.2020.02.043.
• [21] Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg:a systematic review and meta-analysis of randomized controlled trials[J]. J Am Heart Assoc, 2018, 7(24):e011245. DOI:10.1161/JAHA.118.011245.
• [22] Scheller B, Vukadinovic D, Jeger R, et al. Survival after coronary revascularization with paclitaxel-coated balloons[J].J Am Coll Cardiol, 2020, 75(9):1017-1028. DOI:10.1016/j.jacc.2019.11.065.
• [23] Giacoppo D,Alvarez-Covarrubias HA,Koch T,et al.Coronary artery restenosis treatment with plain balloon, drugcoated balloon, or drug-eluting stent:10-year outcomes of the ISAR-DESIRE 3 trial[J]. Eur Heart J,2023,44(15):1343-1357. DOI:10.1093/eurheartj/ehad026.